Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from two vehicle-controlled, randomized phase III studies

Journal of the American Academy of Dermatology

Volumn 48, Issue 6, 2003, Pages 836-845

  Thiboutot, Diane ^a   Thieroff Ekerdt, Ruth ^b   Graupe, Klaus ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; DRUG VEHICLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; FEMALE; GEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAPULOPUSTULAR ROSACEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; ROSACEA; SCORING SYSTEM;

EID: 0038793699     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2003.308     Document Type: Article

References (15)

1. Wilkin JK. Rosacea: pathophysiology and treatment. Arch Dermatol 1994;130:359-62.
2. Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, et al. Standard classification of rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol 2002;46:584-7.
3. Rebora A. The management of rosacea. Am J Clin Dermatol 2002;3:489-96.
4. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol 1999;40:961-5.
5. Bjerke R, Fyrand O, Graupe K. Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulopustular rosacea. Acta Derm Venereol 1999;79:456-9.
6. Carmichael AJ, Mark R, Graupe KA, Zaumseil RP. Topical azelaic acid in the treatment of rosacea. J Dermatol Treat 1993;4(Suppl):S19-22.
7. Bergfeld WF. A lifetime of healthy skin: implications for women. Int J Fertil Womens Med 1999;44:83-95.
8. Passi S. Pharmacology and pharmacokinetics of azelaic acid. Rev Contemp Pharmacother 1993;4:441-7.
9. Bojar RA, Holland KT. Azelaic acid: a review of its antimicrobial properties. Rev Contemp Pharmacother 1993;4:403-14.
10. Passi S, Picardo M, Zompetta C, De Luca C, Breathnach AS, Nazzaro-Porro M. The oxyradical-scavenging activity of azelaic acid in biological systems. Free Radic Res Commun 1991;15:17-28.
11. Akamatsu H, Komura J, Asada Y, Miyachi Y, Niwa Y. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res 1991;283:162-266.
12. Akamatsu H, Oguchi M, Nishijima S, Asada Y, Takahashi M, Ushijima T, et al. The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol Res 1990;282:449-54.
13. Nazzaro-Porro M, Passi S, Picardo M, Balus L, Breathnach AS. L'acido azelaico nella rosacea? G Ital Dermatol Venerol 1991;126:19-27.
14. Thiboutot D. New treatments and therapeutic strategies for acne. Arch Fam Med 2000;9:179-87.
15. Zuber TJ. Rosacea. Prim Care 2000;27:309-18.